Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
View stock
VS
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
View stock

Stock highlights

Stock comparison highlights
Stock name
Novo NordiskJohnson & Johnson
Last price
$38.30$272.42
Currency
USD
USD
$171B$647B
9.9240.81
$3.90$6.58
0.350.21
$1.28$5.28
2.11%1.99%
Sector
HealthHealth
Employees
66,700138,200
Ticker
$NVO$JNJ
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NVO or $JNJ on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.